NCT05715346 - LEV102 Topical Gel in Acquired Blepharoptosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

June 24, 2023

Study Completion Date

June 24, 2023

Conditions

Acquired Blepharoptosis

Interventions

DRUG

LEV102 1.0%

Oxymetazoline ophthalmic gel

DRUG

LEV102 2.0%

Oxymetazoline ophthalmic gel

DRUG

Vehicle

Vehicle ophthalmic gel

Trial Locations (3)

Brian Biesman, M.D, Nashville

Eye Research Foundation, Newport Beach

Steve Yoelin Medical Associates, Newport Beach